AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Hypofibrinogenemia Epidemiology Forecast to 2030: Focus on United States, Japan, Germany, Spain, Italy, France, and the United Kingdom - ResearchAndMarkets.com

December 21, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 21, 2020--

The “Hypofibrinogenemia - Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

Hypofibrinogenemia - Epidemiology Forecast to 2030 delivers an in-depth understanding of the Hypofibrinogenemia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

ADVERTISEMENT

Hypofibrinogenemia Epidemiology

The Hypofibrinogenemia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hypofibrinogenemia epidemiology segmented as the Total Cases of Hypofibrinogenemia, Type-Specific Cases of Hypofibrinogenemia (as congenital and acquired), and Acquired Hypofibrinogenemia cases. The report includes the Prevalent scenario of Hypofibrinogenemia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Hypofibrinogenemia Epidemiology

The epidemiology segment also provides the Hypofibrinogenemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total prevalent population of Hypofibrinogenemia Associated in 7MM countries estimated to be 11,084 cases in 2017.

  • As per the estimates, the United States has the highest Prevalent population of Hypofibrinogenemia
  • Among the EU5 countries, Germany had the highest prevalent population of Hypofibrinogenemia. On the other hand, Spain had the lowest prevalent population with 493 cases in 2017.

Scope of the Report

ADVERTISEMENT

  • Hypofibrinogenemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Hypofibrinogenemia Epidemiology Report and Model provide an overview of the risk factors and global trends of Hypofibrinogenemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Hypofibrinogenemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Hypofibrinogenemia
  • The report provides the segmentation of the Hypofibrinogenemia epidemiology by Prevalent Cases of Hypofibrinogenemia in 7MM
  • The report provides the segmentation of the Hypofibrinogenemia epidemiology by Type-specific Prevalent Cases of Hypofibrinogenemia in 7MM

Report Highlights

  • 11-Year Forecast of Hypofibrinogenemia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Hypofibrinogenemia
  • Prevalent Cases according to segmentation: Type-specific Prevalence of Hypofibrinogenemia, Acquired Hypofibrinogenemia cases

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Hypofibrinogenemia?
  • What are the key findings of Hypofibrinogenemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Hypofibrinogenemia across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of Hypofibrinogenemia?
  • What are the currently available treatments for Hypofibrinogenemia?

Study Period: 2017-2030

The frequency of congenital fibrinogen disorders in the general population is very low. A North American Registry of Rare Bleeding Disorders has been successful in collecting valuable information on inherited fibrinogen disorders and other rare bleeding disorders. Among all the reported fibrinogen disorders in this registry, afibrinogenemia accounted for 24% of cases, hypofibrinogenemia accounted for 38%, and dysfibrinogenemia accounted for 38%.

Key Topics Covered:

1. Key Insights

2. Hypofibrinogenemia: Epidemiology Overview at a Glance

2.1. Patient Share (%) Distribution of Hypofibrinogenemia in 2017

2.2. Patient Share (%) Distribution of Hypofibrinogenemia in 2030

3. Executive Summary

4. Organizations

5. Disease Overview: Hypofibrinogenemia

5.1. Introduction

5.2. Classification

5.3. Signs and Symptoms

5.4. Pathogenesis

5.5. Diagnosis

5.5.1. Differential Diagnosis

5.5.2. Prenatal Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total cases of Hypofibrinogenemia

7. Country-wise Epidemiology of Hypofibrinogenemia

7.1. Assumptions and Rationale

7.2. KOL Views: Epidemiology

7.3. United States

7.3.1. Total Cases of Hypofibrinogenemia in the United States

7.3.2. Type-Specific Cases of Hypofibrinogenemia in the US

7.3.3. Acquired Hypofibrinogenemia cases in the US

7.4. Germany

7.5. France

7.6. Italy

7.7. Spain

7.8. United Kingdom

7.9. Japan

8. Current Treatment Practices

9. Unmet Needs

10. SWOT Analysis

11. Bibliography

12. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/bszjfj

View source version on businesswire.com:https://www.businesswire.com/news/home/20201221005393/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/21/2020 07:41 AM/DISC: 12/21/2020 07:42 AM

http://www.businesswire.com/news/home/20201221005393/en